Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/93834
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Fonseca, Nuno A. | - |
dc.contributor.author | Gregório, Ana C. | - |
dc.contributor.author | Mendes, Vera M. | - |
dc.contributor.author | Lopes, Rui | - |
dc.contributor.author | Abreu, Teresa | - |
dc.contributor.author | Gonçalves, Nélio | - |
dc.contributor.author | Manadas, Bruno | - |
dc.contributor.author | Lacerda, Manuela | - |
dc.contributor.author | Figueiredo, Paulo | - |
dc.contributor.author | Pereira, Marta | - |
dc.contributor.author | Gaspar, Manuela | - |
dc.contributor.author | Colelli, Fabiana | - |
dc.contributor.author | Pesce, Daniela | - |
dc.contributor.author | Signorino, Giacomo | - |
dc.contributor.author | Focareta, Laura | - |
dc.contributor.author | Fucci, Alessandra | - |
dc.contributor.author | Cardile, Francesco | - |
dc.contributor.author | Pisano, Claudio | - |
dc.contributor.author | Cruz, Tony | - |
dc.contributor.author | Almeida, Luís | - |
dc.contributor.author | Moura, Vera | - |
dc.contributor.author | Simões, Sérgio | - |
dc.contributor.author | Moreira, João N. | - |
dc.date.accessioned | 2021-03-23T15:12:53Z | - |
dc.date.available | 2021-03-23T15:12:53Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 17480132 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/93834 | - |
dc.description.abstract | Patients with breast or ovarian cancer have not benefited from improved efficacy with pegylated liposomal doxorubicin relative to free drug, likely due to the limited extent of the enhanced permeability and retention (EPR) effect, further compromising drug bioavailability in the tumor. Herein it is hypothesized that targeting nucleolin overexpressed in tumor endothelial cells (readily accessible from the vascular compartment), besides cancer cells, with PEGASEMP (doxorubicin hydrochloride in a lipid-based pegylated nanoparticle functionalized with a 31-aminoacid peptide targeting nucleolin), lessens the dependence on high systemic exposures and EPR effect for successful tumor targeting. This strategy has resulted in improved intracellular tumor bioavailability of doxorubicin, at low systemic exposure, associated with a safe toxicological profile. Levels of cell surface nucleolin dictated the antitumor activity of PEGASEMP against nucleolin-overexpressing solid tumors of diverse histological origin, evidencing a significant growth inhibition of malignant mesothelioma over the standard of care. Those observations were paralleled by an impairment of the nucleolin-positive vasculature and downregulation of typically overexpressed genes. Patient stratification based on nucleolin mRNA expression correlated with prognosis and enabled identification of breast and mesothelioma tumors that may potentially benefit from PEGASEMP. Overall, a novel principle of drug delivery is presented with potential therapeutic impact across nucleolin-overexpressing human cancers. | pt |
dc.language.iso | eng | pt |
dc.publisher | Elsevier | pt |
dc.relation | POCI-01-0145-FEDER-016390 (acronym: CANCEL STEM) | pt |
dc.relation | Healthy Aging 2020: CENTRO-01-0145-FEDER-000012 | pt |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/234811/EU/EUROpean network of trans-national collaborative RTD in the field of NANOMEDicine | pt |
dc.rights | embargoedAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Nucleolin | pt |
dc.subject | Targeted-drug delivery | pt |
dc.subject | Mesothelioma | pt |
dc.subject | Breast cancer | pt |
dc.subject | Nucleolin-overexpressing cancers | pt |
dc.title | GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure | pt |
dc.type | article | - |
degois.publication.firstPage | 101095 | pt |
degois.publication.title | Nano Today | pt |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1748013221000207#keys0005 | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.nantod.2021.101095 | pt |
degois.publication.volume | 37 | pt |
dc.date.embargo | 2023-04-01 | * |
uc.date.periodoEmbargo | 730 | pt |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | open | - |
item.openairetype | article | - |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.cerifentitytype | Publications | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-2087-4042 | - |
crisitem.author.orcid | 0000-0001-5820-9964 | - |
crisitem.author.orcid | 0000-0003-3449-0522 | - |
Aparece nas coleções: | I&D CNC - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
1-s2.0-S1748013221000207-main.pdf | 15.01 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
10
Visto em 11/nov/2022
Citações WEB OF SCIENCETM
12
Visto em 2/mai/2023
Visualizações de página
257
Visto em 28/ago/2024
Downloads
117
Visto em 28/ago/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons